Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
Randomized, double-blind, placebo controlled clinical trial of immunogenicity, safety and efficacy of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- VENEZUELA
- status
- UNKNOWN
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 2000
- sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- conditions
- Covid19
- interventions
- BIOLOGICAL: Gam-COVID-Vac; BIOLOGICAL: Placebo
- start date
- 2020-11-01
- start date type
- ESTIMATED
- primary completion date
- 2021-10-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT04642339
- Published
- Nov 24, 2020
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT04642339
- Categories
- Covid19
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials